Legend Biotech (LEGN) Q1 2026 earnings review
CARVYKTI Volume Surges, But Scaling Costs Crush Margins
Legend Biotech continues to ride the explosive demand for CARVYKTI, driving a 62% YoY increase in global net trade sales to $597 million. However, the costs of fulfilling this demand have severely impacted profitability. While Collaboration Revenue grew 61% YoY to $298.4 million, the Cost of Collaboration Revenue skyrocketed 152% to $175.4 million due to capacity expansion and depreciation charges. Consequently, the collaboration margin compressed dramatically. Although management maintains its target of company-wide operating profit in 2026, the sudden margin deterioration and an impending $266 million cash recoupment from Janssen highlight the immense financial friction of scaling autologous cell therapies.
🐂 Bull Case
CARVYKTI sales continue accelerating in absolute dollars, reaching $597M in 26Q1. Ex-US markets are driving significant volume, indicating successful geographic expansion.
With major clinical trial dosing phases completed, R&D expenses decelerated by 16% YoY. This operating leverage is crucial for the 2026 profitability target.
🐻 Bear Case
The cost of collaboration revenue grew nearly 2.5x faster than the revenue itself. If capacity expansion costs remain structurally higher, the path to sustained profitability narrows.
$266 million in Janssen advanced funding is now classified as a current liability, meaning Janssen will recoup this amount from Legend's share of pre-tax profits over the next 12 months.
⚖️ Verdict: ⚪
Neutral. The top-line growth is phenomenal and cements CARVYKTI as a best-in-class asset. However, the severe margin compression directly contradicts the narrative of an easy path to 2026 profitability. Scaling cell therapy manufacturing remains a brutal, capital-intensive endeavor.
Key Themes
Collaboration Margin Compression
A massive red flag emerged in the core business model. Cost of collaboration revenue surged 152% YoY to $175.4M, wildly outpacing the 61% growth in collaboration revenue. Management attributed this to 'one-time additional costs incurred for capacity expansion and depreciation charges.' This reversing trend in margins directly contradicts the positive volume narrative and requires immediate monitoring to see if these costs are truly 'one-time' or structural.
Janssen Debt Recoupment Timeline
The $266.0M in 'Collaboration interest-bearing advanced funding' from Janssen has been fully moved to current liabilities. Management explicitly stated they estimate the entire balance will be recouped within the next 12 months from Legend's share of pre-tax profits. This means that even if the collaboration prints cash this year, a massive chunk will bypass Legend's treasury, pressuring near-term free cash flow.
International Markets Driving Adoption
Ex-US collaboration revenue is accelerating rapidly, jumping from $26.7M in 25Q1 to $82.0M in 26Q1 (+207% YoY). As the Tech Lane facility in Europe ramps up commercial supply, international markets are becoming a major pillar of CARVYKTI's growth story.
Clinical Trial Costs Decelerating
R&D expenses fell from $101.9M to $85.7M (-16% YoY). Management noted this was driven by lower expenditures in the cilta-cel clinical program as patient dosing phases for major trials concluded. This is a critical driver for margin improvement, providing necessary operating leverage as the company pivots from a clinical-stage biotech to a commercial-stage powerhouse.
Macro Risk: Tariff Uncertainty
Management proactively addressed the macroeconomic environment, noting potential exposure to future Trump administration tariffs on imported pharmaceutical ingredients and processing materials. While US CARVYKTI supply is manufactured domestically in New Jersey, raw material sourcing remains a vulnerability.
Earlier-Line Treatment Paradigm
CARVYKTI's success is heavily driven by its shift into earlier lines of therapy. Backed by CARTITUDE-4 overall survival data and community setting outreach, physician adoption is expanding the total addressable market far beyond late-line, heavily pre-treated patients.
Surging Commercial Costs
Selling and distribution expenses increased 22% YoY to $50.1 million. While slower than revenue growth, management noted this was driven by sales force expansion and marketing/market access activities. As Legend pushes into the community oncology setting—a highly fragmented market—these costs may remain elevated.
Other KPIs
Reversing positively. While still negative, this is a notable improvement from the -$103.6 million cash burn in 25Q1. The improvement was driven by a smaller net loss and better working capital dynamics, including a decrease in income taxes paid.
Stable. The company holds $646.4M in cash and cash equivalents and $188.2M in time deposits. While total liquidity dropped from $901.9M at the end of 2025, it remains robust enough to fund operations through the projected 2026 profitability inflection point without requiring dilutive equity raises.
Guidance
Management reiterated their target to achieve company-wide operating profit in 2026. This implies a significant acceleration in core profitability, as the company just posted a $49.8M operating loss in 26Q1. Achieving this will require the recent margin compression in the collaboration segment to be strictly temporary.
Key Questions
Margin Normalization
The cost of collaboration revenue jumped 152% YoY, heavily compressing margins. Can you quantify exactly how much of this was 'one-time' capacity expansion versus structurally higher depreciation, and when do you expect collaboration gross margins to normalize back to the ~60% range?
Janssen Recoupment Mechanics
With the $266M in Janssen advanced funding now classified as a current liability, how exactly will the 100% recoupment from pre-tax profits over the next 12 months impact Legend's actual cash inflows from CARVYKTI sales this year?
Community Setting ROI
Selling and distribution expenses rose 22% as you expanded the sales force. What are the early returns on the push into community oncology networks, and is the cost of customer acquisition structurally higher there than in academic centers?
Supply Chain Vulnerability
You flagged potential tariff exposure on imported pharmaceutical ingredients. What percentage of CARVYKTI's raw materials (by cost) are currently sourced from outside the US, and what mitigation strategies are in place?